Orion Corporation will publish its financial result for 2011 on Tuesday, 7 February 2012.
The publication dates of the Interim Reports in 2012 are as follows:
Interim Report 1-3/2012 Tuesday, 24 April 2012
Interim Report 1-6/2012 Tuesday, 31 July 2012
Interim Report 1-9/2012 Tuesday, 23 October 2012
The Annual Report 2011 will be published on the company's website latest on week 10/2012.
The Annual General Meeting is planned to be held on Tuesday, 20 March 2012 in Helsinki.
Orion's financial reports and related presentation material are available on the Group's website at www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for publications and releases.
|Timo Lappalainen |
President and CEO
|Jari Karlson |
Orionintie 1A, FI-02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.